Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases
Neurology International,
Journal Year:
2025,
Volume and Issue:
17(2), P. 26 - 26
Published: Feb. 7, 2025
Alzheimer’s
and
Parkinson’s
are
the
most
common
neurodegenerative
diseases
(NDDs).
The
development
of
aberrant
protein
aggregates
progressive
permanent
loss
neurons
major
characteristic
features
these
disorders.
Although
precise
mechanisms
causing
disease
(AD)
(PD)
still
unknown,
there
is
a
wealth
evidence
suggesting
that
misfolded
proteins,
accumulation
dysfunction
neuroreceptors
mitochondria,
dysregulation
enzymes,
release
neurotransmitters
significantly
influence
pathophysiology
diseases.
There
no
effective
protective
medicine
or
therapy
available
even
with
availability
numerous
medications.
an
urgent
need
to
create
new
powerful
bioactive
compounds
since
number
people
NDDs
rising
globally.
Heterocyclic
have
consistently
played
pivotal
role
in
drug
discovery
due
their
exceptional
pharmaceutical
properties.
Many
clinically
approved
drugs,
such
as
galantamine
hydrobromide,
donepezil
hydrochloride,
memantine
opicapone,
feature
heterocyclic
cores.
As
therapeutic
potential,
heterocycles
intriguing
research
topic
for
drugs
PD
AD.
This
review
aims
provide
current
insights
into
potential
use
targeting
diverse
targets
manage
potentially
treat
patients
AD
PD.
Language: Английский
Paradoxical Boosting of Weak and Strong Spatial Memories by Hippocampal Dopamine Uncaging
Cintia Velázquez-Delgado,
No information about this author
Job Perez-Becerra,
No information about this author
Vladimir Calderón
No information about this author
et al.
eNeuro,
Journal Year:
2024,
Volume and Issue:
11(5), P. ENEURO.0469 - 23.2024
Published: May 1, 2024
The
ability
to
remember
changes
in
the
surroundings
is
fundamental
for
daily
life.
It
has
been
proposed
that
novel
events
producing
dopamine
release
hippocampal
CA1
region
could
modulate
spatial
memory
formation.
However,
role
of
increase
on
weak
or
strong
memories
remains
unclear.
We
show
male
mice
exploring
two
objects
located
a
familiar
environment
5
min
created
short-term
(weak)
cannot
be
retrieved
1
d
later,
whereas
10
exploration
long-term
(strong)
can
later.
Remarkably,
elevation
during
encoding
object
location
(OLMs)
allowed
their
retrieval
later
but
OLMs
promoted
preference
over
after
24
h.
Moreover,
uncaging
did
not
have
effect
diminished
location.
Additionally,
allow
recovery
and
affect
traces.
Finally,
increased
theta
oscillations,
indicating
promotes
recurrent
activation
specific
groups
neurons.
Our
experiments
demonstrate
dopaminergic
modulation
depends
strength
hyperdopaminergic
levels
enhance
experiences
compromise
normal
storage
memories.
Language: Английский
Photostimulation of Locus Coeruleus CA1 catecholaminergic terminals reversed spatial memory impairment in an Alzheimer's disease mouse model.
Research Square (Research Square),
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 22, 2025
Abstract
Rationale
One
of
the
earliest
changes
associated
with
Alzheimer's
disease
(AD)
is
loss
catecholaminergic
terminals
in
cortex
and
hippocampus
originating
from
Locus
Coeruleus
(LC).
This
decline
leads
to
reduced
neurotransmitters
hippocampus,
affecting
synaptic
plasticity
spatial
memory.
However,
it
unclear
whether
restoring
transmission
LC
may
alleviate
memory
deficits
AD.
Objectives
study
investigates
how
optogenetic
stimulation
projections
locus
coeruleus
hippocampal
CA1
region
enhance
disease.
Methods
We
conducted
experiments
using
a
12-month-old
3xTg-AD
mouse
model
(AD-TH),
which
expresses
Cre
recombinase
under
control
tyrosine
hydroxylase
(TH)
gene.
allowed
us
photostimulate
before
performing
two
different
tasks
inducing
long-term
potentiation
(LTP).
Results
Optogenetic
successfully
reversed
impairment
retrieval
aging
AD-TH
mice.
Furthermore,
this
restored
neurotransmitter
levels
enhanced
plasticity,
as
demonstrated
by
an
LTP
protocol.
Conclusions
These
findings
indicate
that
circuitry
(LC)
plays
crucial
role
disrupting
contributing
seen
early
stages
highlights
potential
therapeutic
benefits
targeting
neurons
improve
cognitive
function
patients
Language: Английский
Unscrambling the cellular and molecular threads of Neuroplasticity: Insights into Alzheimer’s disease pathogenesis
Palak Kalra,
No information about this author
Amarjot Kaur Grewal,
No information about this author
Heena Khan
No information about this author
et al.
Neuroscience,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Language: Английский
Exploring the Efficacy and Safety of Nutritional Supplements in Alzheimer’s Disease
Nutrients,
Journal Year:
2025,
Volume and Issue:
17(5), P. 922 - 922
Published: March 6, 2025
Background:
Alzheimer's
disease
(AD)
represents
one
of
the
major
challenges
modern
medicine,
with
a
growing
impact
on
public
health
and
healthcare
systems.
In
recent
years,
dietary
supplements
use
has
been
subject
increasing
interest
as
complementary
strategy
for
prevention
treatment
disease.
Materials
Methods:
A
Review
reviews
was
conducted
following
PRISMA
guidelines
REAPPRAISED
checklist
to
evaluate
efficacy
safety
supplement
in
AD.
The
search,
performed
across
scientific
databases,
identified
54
relevant
articles,
including
53
mini-review,
after
applying
specific
inclusion
criteria
removing
duplicates.
Results:
body
evidence
suggests
that
some
may
help
reduce
cognitive
decline,
inflammation,
target
mechanisms
behind
However,
many
these
are
still
under
investigation,
mixed
results
highlighting
need
high-quality
research.
key
challenge
is
lack
data
optimal
dosages,
administration
duration,
long-term
safety,
which
limits
clinical
guidelines.
Some
studies
have
reported
positive
effects
from
regimens,
such
curcumin
(800
mg/day),
omega-3
fatty
acids
(2
g/day),
resveratrol
(600
mg/day).
Other
supplements,
like
phosphatidylserine
(300
multinutrient
formulations,
probiotics,
vitamin
E
(2000
IU/day),
melatonin
(3-10
also
show
benefits,
though
study
variability
makes
conclusions
uncertain.
Conclusions:
While
certain
potential
mitigating
decline
AD,
inconsistent
findings
gaps
dosage
highlight
rigorous,
large-scale
trials.
Future
research
should
focus
personalized,
multimodal
strategies
integrating
targeted
supplementation,
patterns,
microbiota-gut-brain
interactions
enhanced
neuroprotection.
Language: Английский
Neurotrophic factor alpha 1 gene therapy in Alzheimer’s disease: scope and advancements
Frontiers in Molecular Neuroscience,
Journal Year:
2025,
Volume and Issue:
18
Published: April 1, 2025
Alzheimer's
disease
(AD)
is
the
leading
cause
of
dementia,
accounting
for
60-80%
all
cases
globally.
Hallmark
pathologies
AD
include
accumulation
amyloid
β
peptide
and
phosphorylated
tau,
to
neuronal
circuit
dysfunction,
defective
axonal
transport,
neurotransmitter
system
(NTS)
abnormalities.
Disruptions
in
acetylcholine,
GABA,
dopamine,
serotonin,
glutamate
levels,
as
well
loss
cholinergic,
GABAergic,
monoaminergic
neurons,
contribute
progression
AD.
Additionally,
neurotrophic
factors
like
brain-derived
factor
(BDNF)
nerve
growth
(NGF)
are
significantly
reduced
AD,
impacting
health
synaptic
integrity.
This
review
highlights
emerging
role
alpha
1
(NF-α1),
also
known
carboxypeptidase
E,
NF-α1
shows
neuroprotective
neurogenesis-promoting
properties,
offering
potential
therapeutic
interventions.
The
compares
gene
therapy
with
other
neurotrophin-based
treatments,
providing
insights
into
its
efficacy
management.
Language: Английский
Entorhinal cortex–hippocampal circuit connectivity in health and disease
Frontiers in Human Neuroscience,
Journal Year:
2024,
Volume and Issue:
18
Published: Sept. 20, 2024
The
entorhinal
cortex
(EC)
and
hippocampal
(HC)
connectivity
is
the
main
source
of
episodic
memory
formation
consolidation.
entorhinal–hippocampal
(EC-HC)
connection
classified
as
canonically
glutamatergic
and,
more
recently,
has
been
characterized
a
non-canonical
GABAergic
connection.
Recent
evidence
shows
that
both
EC
HC
receive
inputs
from
dopaminergic,
cholinergic,
noradrenergic
projections
modulate
mnemonic
processes
linked
to
encoding
consolidation
memories.
In
present
review,
we
address
latest
findings
on
EC-HC
role
neuromodulations
during
mechanisms
memories
highlight
value
cross-species
approach
unravel
underlying
cellular
known.
Furthermore,
discuss
how
early
neurodegeneration
may
contribute
dysfunction
observed
in
aging
Alzheimer’s
disease
(AD).
Finally,
described
exercise
be
fundamental
tool
prevent
or
decrease
neurodegeneration.
Language: Английский
Unveiling the Therapeutic Potential of Kelulut (Stingless Bee) Honey in Alzheimer’s Disease: Findings from a Rat Model Study
Antioxidants,
Journal Year:
2024,
Volume and Issue:
13(8), P. 926 - 926
Published: July 30, 2024
Alzheimer's
disease
(AD)
poses
a
major
worldwide
health
challenge
because
of
its
profound
impact
on
cognitive
abilities
and
overall
well-being.
Despite
extensive
research
numerous
clinical
trials,
therapeutic
options
remain
limited.
Our
study
aimed
to
investigate
the
potential
Kelulut
honey
(KH)
as
novel
agent
for
addressing
multifactorial
pathology
AD.
We
tried
evaluate
disease-attenuating
neuroprotective
KH
in
intrahippocampally
induced
AD
rat
model
by
utilizing
histochemistry
enzyme-linked
immunosorbent
assay
(ELISA)
studies.
A
total
26
male
Sprague
Dawley
rats
weighing
~280-380
g
were
randomly
divided
into
three
groups:
Control,
AD-induced
(Aβ),
treated
with
(Aβ+KH).
The
latter
two
groups
underwent
stereotaxic
surgery,
where
6.25
µg
amyloid
β
Language: Английский
Dopamine agonist Rotigotine mitigates lipopolysaccharide-induced neuroinflammation and memory impairment in mice
Metabolic Brain Disease,
Journal Year:
2024,
Volume and Issue:
40(1)
Published: Nov. 20, 2024
Language: Английский
Exploring the Impact of Game Elements and Technological Platforms on Dementia Rehabilitation: A Scoping Review
International Journal of Human-Computer Interaction,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 22
Published: Oct. 18, 2024
One
effective
strategy
to
improve
the
quality
of
life
for
people
with
dementia
(PWD)
is
rehabilitation,
though
patients
often
show
reluctance
due
disease's
effects.
A
trending
motivational
approach
gamification.
However,
most
research
in
this
field
has
focused
on
medical
or
technical
aspects
system
development,
less
attention
given
role
game
elements
patient
experience.
In
study,
a
scoping
review
based
PRISMA
method
was
conducted
gamified
rehabilitation
systems,
focusing
gamification
elements,
and
interaction
technological
platforms.
By
reviewing
46
studies,
we
extracted
pyramid,
platforms,
methods,
compared
them
previous
studies
PWD
interactions.
This
analysis
identified
opportunities
challenges
future
research.
Additionally,
nine
factors
user
experience
design
systems
were
presented
results.
Language: Английский